BIOTECH LIMITED

Pursuant to the statutory registers of the Hong Kong Companies Registry, BIOTECH LIMITED was officially incorporated on 2012-04-16 (standing for 14 years). Official cross-departmental records confirm its current legal status is [Live / In Operation], maintaining valid operational standing under Hong Kong SAR law (Verified: October 2026).

The statutory identifiers for this corporation issued by Hong Kong SAR authorities are: 1. Business Registration Number (BRN / Unique Business Identifier UBI): [59652587] (effective from 27 December 2023, this 8-digit number serves as the official cross-departmental primary identifier and tax ID); 2. Company Registration Number (CRN): [1729749] (historical archive number issued by Companies Registry). In international banking KYC, trade bills of lading, and cross-border contracts, these two numbers uniquely confirm entity legitimacy.

Under Hong Kong law, incorporated companies do not maintain a 'legal representative' position; the Board of Directors exercises supreme statutory management authority. Under the New Inspection Regime of the Companies Ordinance, public inspection protects directors' personal identification by displaying correspondence addresses and masked ID numbers. To inspect certified directorship history, shareholding structure (Form NAR1), Significant Controllers Register (SCR), and multi-tier beneficial ownership (UBO), formal certified registers must be retrieved through statutory registry inspection or corporate due diligence procedures.

According to the official statutory records of the Companies Registry, BIOTECH LIMITED has officially recorded 3 legal name change(s): [Shareck Instrument Co., Limited (雪瑞儀器有限公司) (effective 2012-04-16)], [CHANGSHA LABTECH GROUP LIMITED (effective 2013-05-20)], [LabCore Tech Limited (effective 2026-01-04)]. The current registered legal name was confirmed upon issuance of a Certificate of Change of Name by the Registrar of Companies. Screening former names is essential to uncover historical litigation and corporate credit track records.

Yes. Official records of the Hong Kong Companies Registry verify that BIOTECH LIMITED maintains a cumulative statutory archive of 20 filing record(s) on file. Under the Companies Ordinance (Cap. 622), the corporation's active governance and equity standing are documented through Annual Returns (Form NAR1), constitutional Articles of Association, and statutory officer update filings (Form ND2A). Official certified extracts and CPA Certified True Copies (CTC) are accessible pursuant to statutory procedures.

According to multi-dimensional checks across Hong Kong statutory authorities: 1. Regulatory Licences: Cross-referenced across all Hong Kong statutory regulatory registers (including HKMA, SFC, TCSP, Customs MSO/DPMS), this entity holds no special financial licensing, operating as an ordinary commercial company limited by shares; 2. Judicial Screening (Litigation & Winding-Up): judicial screening has identified compulsory winding-up petition records (HCCW docket) filed against the company in the High Court of Hong Kong, indicating critical legal solvency or liquidation risk. Immediate verification of petition details is recommended.

The statutory registered office (corporate headquarters on official record) of BIOTECH LIMITED is situated at: [ROOM S032, 2/F, THE CAPITAL, 61-65 CHATHAM ROAD SOUTH, TSIM SHA TSUI, HONG KONG]. Pursuant to Section 658 of the Companies Ordinance (Cap. 622) of Hong Kong, all companies registered in Hong Kong must maintain an official registered office within the Hong Kong SAR where official communications, regulatory notices, and legal court process may be lawfully served.

In Hong Kong company law, official corporate validity is established through statutory registration rather than domain filings. The Hong Kong Companies Registry does not maintain an Internet domain registry. Commercial partners verifying BIOTECH LIMITED should authenticate its active standing via its 8-digit Business Registration Number (BRN: 59652587) and certified registry dossiers to prevent cross-border impersonation risks.